Findings aid antiviral drug discovery
Many viral infections, such as the common cold, cause mild illnesses that the body’s immune system eventually defeats. But when viruses cause severe disease, doctors have few options for effective treatment.
Studying mice with a variety of viral infections, scientists at Washington University School of Medicine in St. Louis have demonstrated a way to dial up the body’s innate immune defenses while simultaneously attacking a protein that many viruses rely on to replicate.
The findings, published Oct. 19 in Nature Immunology, reveal previously unknown weapons in the body’s antiviral immune arsenal and provide guidelines for designing drugs that could be effective against a broad range of viruses. The strategy involves enhancing the body’s interferon signaling system, long understood to be a vital part of antiviral defenses.
“We’ve discovered a new component of the interferon system,” said senior author Michael J. Holtzman, MD, the Selma and Herman Seldin Professor of Medicine. “It does something that other components don’t do, and it works on both sides of the fence: It dials up the body’s internal genes that fight viruses, and it attacks viral proteins directly.”
Holtzman and lead author Yong Zhang, PhD, an instructor in pulmonary medicine, suspect that the researchers’ one-two punch against the virus may explain the large difference in survival rates between control mice and mice genetically engineered to have increased signaling in their interferon systems.
When infected with encephalomyocarditis virus, which causes severe damage to vital organs including the brain, heart and pancreas, 97 percent of the genetically engineered mice survived, compared with none of the control mice. Even when the concentration of the injected virus was increased 100-fold, 82 percent of the genetically altered mice survived. And at 100-fold lower concentrations, all genetically engineered mice survived the infection, compared with only 25-28 percent of the control mice.
Holtzman pointed out that past research by other groups has shown that increasing the amount of interferon directly results in some improvements in fighting viruses, but not to the same extent as the current work. In addition, more modest improvements shown by other investigators usually are accompanied by autoimmune problems resulting from the chronically activated immune response. Despite the strong antiviral immune response seen in the new study, Holtzman and his colleagues reported no evidence of autoimmune disease in these mice.
The Latest on: Antiviral immune response
via Google News
The Latest on: Antiviral immune response
- 'I have a breathing problem,' yells maskless Trader Joe's shopper who was kicked out of store in viral videoon June 27, 2020 at 2:00 pm
A woman shopping without a mask at a California Trader Joe's caused a scene Friday, calling employees "Democratic pigs" and screaming profanities.
- How the Coronavirus Short-Circuits the Immune Systemon June 26, 2020 at 6:03 pm
In a disturbing parallel to H.I.V., the coronavirus can cause a depletion of important immune cells, recent studies found.
- HEALTH Q&A: Am I immune to COVID-19 if I have antibodies?on June 24, 2020 at 12:42 pm
Q. Am I immune to coronavirus if tests show I have antibodies?A. Perhaps the most important question now about COVID-19 is the degree to which a prior ...
- Repertoire Immune Medicines Receives Funding From COVID-19 High Performance Computing Consortiumon June 24, 2020 at 5:11 am
Repertoire Immune Medicines, a clinical-stage biotech company tooled to decode and deploy the immune system across multiple major diseases, today announced that it has received funding from the ...
- How suppressing the immune system can save lives in severe COVID-19 caseson June 23, 2020 at 7:47 pm
An Oxford University-led trial testing a commonly available immunosuppressive drug on COVID-19 patients has found the cheap steroid significantly reduces deaths when administered to severely sick ...
- Researchers use stem cells to model the immune response to COVID-19on June 23, 2020 at 11:29 am
Two members of the UCLA Broad Stem Cell Research Center have received a grant for work that could be helpful in developing a vaccine.
- BetterLife Pharma (OTCQB:BETRF) Looks to Immune Response Drug Interferon a2b as Potential Therapeutic for COVID-19on June 19, 2020 at 4:57 am
BetterLife Pharma (OTCQB:BETRF) (CSE:BETR) (FRANKFURT: NPAT), an emerging clinical stage pharmaceutical development ...
- Virus co-opts immune protein to avoid antiviral defenceson June 16, 2020 at 8:58 am
By discovering a trick the hepatitis C virus uses to evade the immune system, scientists have identified a new antiviral defense system that could be used to treat many virus infections, according to ...
- Hepatitis C virus co-opts an immune protein to evade antiviral defenseson June 15, 2020 at 5:00 pm
Viruses have many strategies to avoid immune system defenses ... This happened because PKR was not there to identify the virus and trigger antiviral defenses. "These findings reveal a new antiviral ...
- COVID-19 immune response may remain stable for two months after diagnosison June 15, 2020 at 6:25 am
Initial results from an antibody testing study have revealed that COVID-19 antibodies remain stable in the blood of the majority of infected individuals almost two months after diagnosis and possibly ...
via Bing News